Member-only story
A novel transferrin receptor 1-targeted enzyme system alleviates tumor hypoxia, markedly improving radiotherapeutic efficacy and setting a new standard for precision oncology in nasopharyngeal carcinoma.
Enhanced Radiotherapy for Nasopharyngeal Cancer
Precision Nanozyme Delivery Enhances Radiotherapy in NPC
On February 13, 2025, a collaborative study published in Nature Communications introduced a groundbreaking approach to enhancing the effectiveness of radiotherapy for nasopharyngeal carcinoma (NPC). This comprehensive research initiative involved esteemed researchers from the Institute of Biophysics of the Chinese Academy of Sciences, the Fifth Affiliated Hospital of Sun Yat-sen University, and Guangxi Medical University.
Understanding Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is a malignant tumor arising from the nasopharyngeal epithelium. The treatment of NPC poses unique challenges, primarily due to its pronounced hypoxic environment, which can lead to increased resistance to traditional therapies and a high incidence of tumor recurrence and metastasis.
